BXL-628 is primarily investigated for its potential therapeutic applications in the treatment of benign prostatic hyperplasia (BPH). It functions as a selective vitamin D receptor agonist, which helps in regulating cell growth and differentiation in the prostate gland. By targeting the vitamin D pathway, it aims to reduce prostate enlargement and alleviate associated urinary symptoms. Additionally, its mechanism may offer a novel approach to managing BPH with potentially fewer side effects compared to traditional therapies. Research is ongoing to explore its efficacy and safety in clinical settings.